Regulated information

Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon

Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan.

September 2015 year-to-date sales up 8.7% to €251.8 million

Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.

VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs

Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs.

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french)

Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites
Internet de :
- Vétoquinol (www.vetoquinol.com)
- l’AMF (www.amf-france.org)

Vétoquinol is eligible for new PEA-PME funds

Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree
n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-
1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015.

Q1 2015 sales show solid growth at €81.3 million (up +11.0%)

Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014.

Reference products up +13.2%. net income up +9.3%

Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements.

Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration

Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.

2014 sales up 5.2% to €315.3 million

The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014.

Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is
launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock.
The products are being brought to market by the Group and its subsidiaries in
both domestic and export markets.

Vétoquinol appoints RÉGIS VIMAL DU MONTEIL Group Finance and Legal Director

November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as
Group Legal and Financial Director.

Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan

November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing
Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and
Marbocyl® 10% antibiotics for livestock, through collaboration with Meiji Seika
Kaisha, Ltd.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

Mise à disposition ou de consultation du rapport financier semestriel 2010 (french)

Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur
le site Internet de la société : www.vetoquinol.com, rubrique « Investisseurs & Journalistes ».

Strong Results in the first half of 2010

The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version)

The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.